Cite
Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings.
MLA
Tanaka, Nobuyuki, et al. “Effect of Reclassification of the IMDC Model in Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy in the First-Line and Second-Line Settings.” Urologic Oncology, vol. 34, no. 7, July 2016, p. 293.e17-293.e25. EBSCOhost, https://doi.org/10.1016/j.urolonc.2016.02.023.
APA
Tanaka, N., Mizuno, R., Shirotake, S., Ito, K., Yasumizu, Y., Masunaga, A., Ito, Y., Miyazaki, Y., Hagiwara, M., Kanao, K., Mikami, S., Nakagawa, K., Momma, T., Masuda, T., Asano, T., Oyama, M., & Oya, M. (2016). Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings. Urologic Oncology, 34(7), 293.e17-293.e25. https://doi.org/10.1016/j.urolonc.2016.02.023
Chicago
Tanaka, Nobuyuki, Ryuichi Mizuno, Suguru Shirotake, Keiichi Ito, Yota Yasumizu, Ayako Masunaga, Yujiro Ito, et al. 2016. “Effect of Reclassification of the IMDC Model in Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy in the First-Line and Second-Line Settings.” Urologic Oncology 34 (7): 293.e17-293.e25. doi:10.1016/j.urolonc.2016.02.023.